MARKET

KYMR

KYMR

Kymera Therapeutics, Inc.
NASDAQ
79.03
+1.53
+1.97%
Pre Market: 79.20 +0.17 +0.22% 08:19 03/16 EDT
OPEN
78.18
PREV CLOSE
77.50
HIGH
81.25
LOW
77.10
VOLUME
1
TURNOVER
0
52 WEEK HIGH
103.00
52 WEEK LOW
19.45
MARKET CAP
6.45B
P/E (TTM)
-21.4464
1D
5D
1M
3M
1Y
5Y
1D
U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics
Reuters · 2h ago
Weekly Report: what happened at KYMR last week (0309-0313)?
Weekly Report · 2h ago
KYMERA THERAPEUTICS INC <KYMR.O>: JEFFERIES ASSUMES COVERAGE WITH BUY RATING; PRICE TARGET $110 VS $122
Reuters · 4h ago
Kymera Therapeutics COO Jeremy G Chadwick Disposes of Common Shares
Reuters · 4d ago
Kymera Therapeutics to present KT-621 Phase 1b data at AAD 2026 annual meeting
Reuters · 6d ago
Kymera Therapeutics To Present Eczema Drug Trial Results At Major Dermatology Conference
Benzinga · 6d ago
KYMERA THERAPEUTICS ANNOUNCES LATE-BREAKING ORAL PRESENTATION OF KT-621 PHASE 1B DATA AT THE AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING
Reuters · 6d ago
Weekly Report: what happened at KYMR last week (0302-0306)?
Weekly Report · 03/09 09:56
More
About KYMR
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.

Webull offers Kymera Therapeutics Inc stock information, including NASDAQ: KYMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KYMR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KYMR stock methods without spending real money on the virtual paper trading platform.